12:00 AM
Jan 23, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Lucentis ranibizumab regulatory update

Novartis said China's State Food and Drug Administration (SFDA) approved Lucentis ranibizumab to treat wet age-related macular degeneration (AMD). The company, which plans to launch the product in China next half, said...

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >